{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinol&page=12", "query": { "intervention": "Platinol", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1786, "total_pages": 179, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinol&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinol&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:49:34.271Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00580372", "title": "UARK 89-001 Phase II Study of Intensive \"TOTAL THERAPY\" For Untreated or Minimally Treated Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "VAD", "type": "DRUG" }, { "name": "High-Dose cyclophosphamide", "type": "DRUG" }, { "name": "Hemopoietic stem cell procurement", "type": "PROCEDURE" }, { "name": "EDAP", "type": "DRUG" }, { "name": "Autologous Hemopoietic Stem Cell Transplant 1", "type": "PROCEDURE" }, { "name": "Autologous Hemopoietic Stem Cell Transplant 2", "type": "PROCEDURE" }, { "name": "Maintenance", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 231, "start_date": "2002-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2016-09-20", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580372" }, { "nct_id": "NCT01342172", "title": "Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2011-03", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 3, "location_summary": "Bethesda, Maryland • New York, New York • Salt Lake City, Utah", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01342172" }, { "nct_id": "NCT00981656", "title": "Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Three-Dimensional Conformal Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 37, "start_date": "2009-11", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 13, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Fall River", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00981656" }, { "nct_id": "NCT03732677", "title": "Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1063, "start_date": "2018-11-16", "completion_date": "2027-11-08", "has_results": true, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03732677" }, { "nct_id": "NCT00070629", "title": "CPG 7909 Injection in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "CPG 7909", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2003-05", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2009-02-10", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 17, "location_summary": "Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more", "locations": [ { "city": "Gilroy", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070629" }, { "nct_id": "NCT00832637", "title": "Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Cholangiocellular Carcinoma", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Bile Duct Cancer", "Periampullary Adenocarcinoma", "Gallbladder Cancer", "Extrahepatic Bile Duct Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Mexico Cancer Research Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2007-08", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2018-06-29", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 2, "location_summary": "San Francisco, California • Albuquerque, New Mexico", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00832637" }, { "nct_id": "NCT00249977", "title": "Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Cancer" ], "interventions": [ { "name": "Capecitabine in Combination with Cisplatin and Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2010-01-07", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249977" }, { "nct_id": "NCT05386550", "title": "Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Xevinapant", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2022-10-06", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05386550" }, { "nct_id": "NCT02177838", "title": "Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Verrucous Carcinoma of the Larynx", "Tongue Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "external beam radiation therapy", "type": "RADIATION" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2015-03-25", "completion_date": "2019-08-22", "has_results": true, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 1, "location_summary": "Newark, New Jersey", "locations": [ { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02177838" }, { "nct_id": "NCT01936974", "title": "(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Peritoneal Carcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Western Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2013-09", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-02-20", "last_synced_at": "2026-11-15T12:49:34.271Z", "location_count": 1, "location_summary": "Goodyear, Arizona", "locations": [ { "city": "Goodyear", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01936974" } ] }